Information Provided By:
Fly News Breaks for February 21, 2018
TXMD
Feb 21, 2018 | 06:51 EDT
Jefferies analyst Matthew Andrews believes 2018 is set up to be a "transformative" year for TherapeuticsMD with two FDA approvals, which he notes is a rarity in small-cap biotech. Finalization of a $200M term loan prior to TX-004HR approval will remove any financing overhang and helps fund both drugs' launches, Andrews tells investors in a research note. He views the stock as undervalued and thinks TX-001HR can become the vasomotor symptoms "gold-standard drug" with $2B-plus in sales. The analyst keeps a Buy rating on TherapeuticsMD with a $15 price target.
News For TXMD From the Last 2 Days
There are no results for your query TXMD